. 2021 Jan-Mar;14(1):27–32. doi: 10.5935/1984-0063.20190149

Table 2.

Changes in mean components of Pittsburgh questionnaire and actigraphic indices before and after one year in both olanzapine and quetiapine groups

	Variables	Quetiapine Group		P	Olanzapine Group		P	P
	Variables	Baseline Mean± SD	Outcome Mean± SD	Within the group	Baseline Mean± SD	Outcome Mean± SD	Within the group	Between the two groups after treatment
PSQI	SSQ	2.33±.76	1.22±.73	<0.001^*	2.27±.82	1.63±.84	0.005*	0.112^***
	SL	2.66±.48	2±.68	0.001^*	2.45±.59	1.95±.65	0.005^*	0.861^***
	SDU	2.50±.70	1.94±.80	0.013^*	2.31±.71	1.68±.77	0.001^*	0.381^***
	SE	2.66±.84	2.11±1.02	0.031^*	2.45±.91	1.63±1.13	0.009^*	0.209^***
	SDB	1.66±.68	1.16±.38	0.013^*	1.63±.58	1.40±.50	0.166^*	0.199^***
	USM	2.16±1.24	2.16±1.20	0.100^*	1.86±1.24	1.81±1.00	0.836^*	0.240^***
	DD	1.66±.90	1.27±.57	0.134^*	1.72±.93	1.22±.75	0.008^*	0.619^***
	TPS	15.94±2.89	11.77±2.43	<0.001^*	14.77±2.87	11.36±3.06	0.001^*	0.757^***
Actigraphy	TST	339.78±91.51	416.30±48.58	0.006^**	373.31±68.94	381.73±56.96	0.592^**	0.049^****
	SE	77.49±19.22	92.53±6.84	0.002^*	78.79±13.14	83.60±9.13	0.149^*	0.209^***
	SL	27.26±37.83	24.02±27.27	0.679^*	25.43±17.22	27.18±14.33	0.958^*	0.045^***
	WASO	11.72±14.84	2±2.47	<0.001^*	7.27±4.47	1.54±1.53	<0.001^*	0.778^***

Data were presented as mean ± standard deviation:

Wilcoxon Signed Ranks Test;

^**

Paired t test;

^***

Mann-Whitney U;

^****

Independent T; SSQ: Subjective sleep quality; SL: Sleep latency; SDU: Sleep duration; SE: Sleep efficiency; SDB: Sleep disturbance; USM: Use of sleep medication; DD: Daytime dysfunction; TPS: Total PSQI Score; TST: Total sleep time; WASO: Wake up after onset sleep.